Markets

Recro Pharma (REPH) in Focus: Stock Gains 6.5% - Tale of the Tape

Recro Pharma, Inc. ( REPH ) was a big mover last session with its shares rising over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company as the stock is now trading above the past one month's volatile price range of $6.02 to $7.28.

This clinical stage specialty pharmaceutical company has seen no estimate revision in the last 7 days. The Zacks Consensus Estimate hasn't been in trend either. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Recro Pharma currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Investors interested in the Med-Drugs industry may consider better-ranked stocks like Aeolus Pharmaceuticals Inc. ( AOLS ), Ariad Pharmaceuticals Inc. ( ARIA ) and Ohr Pharmaceutical, Inc. ( OHRP ). All the three stocks sport a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

RECRO PHARMA (REPH): Get Free Report

AEOLUS PHARMACT (AOLS): Get Free Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

OHR PHARMACEUT (OHRP): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

REPH NBSE AOLS

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More